Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2018

01-06-2018 | Complications of Antiretroviral Therapy (GA McComsey, Section Editor)

HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers

Authors: Kaku So-Armah, Matthew S. Freiberg

Published in: Current HIV/AIDS Reports | Issue 3/2018

Login to get access

Abstract

Purpose of Review

The objective of this review is to provide an update on the link between HIV infection and cardiovascular disease (CVD). We will focus our review mainly on literature describing clinical CVD events and understudied topics of importance.

Recent Findings

Heart failure, peripheral artery disease, and stroke are CVD modalities deserving more attention in the context of HIV infection in the highly active antiretroviral therapy era. Incidence data on clinical CVD from HIV populations in low- and middle-income countries are limited. Multisubstance use is common in HIV, but understudied as a moderator or mediator of the association between HIV and CVD. CVD risk assessment in HIV remains challenging, but new research into novel biomarkers may provide further insights. There is also a need for inclusion of non-biologic factors in our attempts to understand, quantify, and predict CVD risk among PLWHA.

Summary

Significant attention has been paid to generating and testing hypotheses to understand the mechanisms of myocardial infarction in HIV. Similar attention is deserving for heart failure, PAD, stroke, and cardiovascular disease risk in resource-limited settings and among substance users with HIV.
Appendix
Available only for authorised users
Literature
1.
Stein JH, Currier JS, Hsue PY. Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us? JACC Cardiovasc Imaging. 2014;7(5):515–25.PubMedPubMedCentralCrossRef
2.
Sun D, Wu Y, Yuan Y, Wang Y, Liu W, Yang J. Is the atherosclerotic process accentuated under conditions of HIV infection, antiretroviral therapy, and protease inhibitor exposure? Meta-analysis of the markers of arterial structure and function. Atherosclerosis. 2015;242(1):109–16.PubMedCrossRef
3.
4.
D’Ascenzo F, Cerrato E, Calcagno A, Grossomarra W, Ballocca F, Omede P, et al. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis. 2015;240(1):197–204.PubMedCrossRef
5.
Dorjee K, Baxi SM, Reingold AL, Hubbard A. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. BMC Infect Dis. 2017;17(1):708.PubMedPubMedCentralCrossRef
6.
Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med. 2016;14:61.PubMedPubMedCentralCrossRef
7.
Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Inf Secur. 2000;40(3):282–4.
8.
Lumsden RH, Bloomfield GS. The causes of HIV-associated cardiomyopathy: a tale of two worlds. Biomed Res Int 2016; 2016:8196560, 1, 9.
9.
• Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study. JAMA Cardiol. 2017;2(5):536–46. Documents independent association of HIV infection with incident heart failure (including type heart failure) in the combination ART era using a behaviorally and demographically similar comparator group of uninfected people. PubMedPubMedCentralCrossRef
10.
Al-Kindi SG, ElAmm C, Ginwalla M, Mehanna E, Zacharias M, Benatti R, et al. Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities. Int J Cardiol. 2016;218:43–6.PubMedPubMedCentralCrossRef
11.
Steverson AB, Pawlowski AE, Schneider D, Nannapaneni P, Sanders JM, Achenbach CJ, et al. Clinical characteristics of HIV-infected patients with adjudicated heart failure. Eur J Prev Cardiol. 2017;24(16):1746–58.PubMedCrossRefPubMedCentral
12.
So-Armah KA, Lim JK, Lo Re V, Tate JP, Chung-Chou HC, Butt AA, et al. FIB-4 stage of liver fibrosis predicts incident heart failure among HIV infected and uninfected patients. Hepatology. 2017;66:1286–95.PubMedCrossRef
13.
White JR, Chang CC, So-Armah KA, Stewart JC, Gupta SK, Butt AA, et al. Depression and human immunodeficiency virus infection are risk factors for incident heart failure among veterans: veterans aging cohort study. Circulation. 2015;132(17):1630–8.PubMedPubMedCentralCrossRef
14.
Schwarze-Zander C, Pabst S, Hammerstingl C, Ohlig J, Wasmuth JC, Boesecke C, et al. Pulmonary hypertension in HIV infection: a prospective echocardiographic study. HIV Med. 2015;16(9):578–82.PubMedCrossRef
15.
Brittain EL, Duncan MS, Chang J, Patterson OV, DuVall SL, Brandt CA, et al. Increased echocardiographic pulmonary pressure in HIV-infected and uninfected individuals in the veterans aging cohort study. Am J Respir Crit Care Med. 2017
16.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.PubMedCrossRef
17.
Lourenco AP, Leite-Moreira AF, Balligand JL, Bauersachs J, Dawson D, de Boer RA, et al. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2017;
18.
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.PubMedCrossRef
19.
Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013;30(8):613–28.PubMedPubMedCentralCrossRef
20.
High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012;60(Suppl 1):S1–18.PubMedCrossRef
21.
Smilowitz NR, Gupta N, Guo Y, Coppola JT, Bangalore S. Influence of human immunodeficiency virus seropositive status on the in-hospital management and outcomes of patients presenting with acute myocardial infarction. J Invasive Cardiol. 2016;28(10):403–9.PubMed
22.
Singh V, Mendirichaga R, Savani GT, Rodriguez AP, Dabas N, Munagala A, et al. Coronary revascularization for acute myocardial infarction in the HIV population. J Interv Cardiol. 2017;30(5):405–14.PubMedCrossRef
23.
Uriel N, Nahumi N, Colombo PC, Yuzefpolskaya M, Restaino SW, Han J, et al. Advanced heart failure in patients infected with human immunodeficiency virus: is there equal access to care? J Heart Lung Transplant. 2014;33(9):924–30.PubMedCrossRef
24.
Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–40.PubMedCrossRef
25.
McDermott MM. Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia. Circ Res. 2015;116(9):1540–50.PubMedPubMedCentralCrossRef
26.
27.
Knudsen A, Malmberg CA, Kjaer A, Lebech AM. Low prevalence of peripheral arterial disease in a cross-sectional study of Danish HIV-infected patients. Infect Dis (Lond). 2015;47(11):776–82.CrossRef
28.
Qaqa AY, DeBari VA, Isbitan A, Mohammad N, Sison R, Slim J, et al. The role of postexercise measurements in the diagnosis of peripheral arterial disease in HIV-infected patients. Angiology. 2011;62(1):10–4.PubMedCrossRef
29.
Sharma A, Holman S, Pitts R, Minkoff HL, Dehovitz JA, Lazar J. Peripheral arterial disease in HIV-infected and uninfected women. HIV Med. 2007;8(8):555–60.PubMedCrossRef
30.
Qaqa AY, Debari VA, El-Kersh K, Sison R, Isbitan A, Mohammad N, et al. Epidemiologic aspects of abnormal ankle brachial index in the HIV infected population. Int Angiol. 2012;31(3):227–33.PubMed
31.
Johns K, Saeedi R, Mancini GB, Bondy G. Ankle brachial index screening for occult vascular disease is not useful in HIV-positive patients. AIDS Res Hum Retrovir. 2010;26(9):955–9.PubMedCrossRef
32.
Bernal E, Masia M, Padilla S, Hernandez I, Gutierrez F. Low prevalence of peripheral arterial disease in HIV-infected patients with multiple cardiovascular risk factors. J Acquir Immune Defic Syndr. 2008;47(1):126–7.PubMedCrossRef
33.
Olalla J, Salas D, Del Arco A, De la Torre J, Prada J, Machin-Hamalainen S, et al. Ankle-branch index and HIV: the role of antiretrovirals. HIV Med. 2009;10(1):1–5.PubMedCrossRef
34.
Kwiatkowska W, Knysz B, Arczynska K, Drelichowska J, Czarnecki M, Gasiorowski J, et al. Peripheral arterial disease and ankle-brachial index abnormalites in young and middle-aged HIV-positive patients in lower Silesia, Poland. PLoS One. 2014;9(12):e113857.PubMedPubMedCentralCrossRef
35.
Periard D, Cavassini M, Taffe P, Chevalley M, Senn L, Chapuis-Taillard C, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis. 2008;46(5):761–7.PubMedCrossRef
36.
Gutierrez F, Bernal E, Masia M. Considerations on ankle-brachial index interpretation in HIV-1 infected patients. HIV Med 2009; 10(6):395; author reply 395-396.
37.
Palacios R, Alonso I, Hidalgo A, Aguilar I, Sanchez MA, Valdivielso P, et al. Peripheral arterial disease in HIV patients older than 50 years of age. AIDS Res Hum Retrovir. 2008;24(8):1043–6.PubMedCrossRef
38.
Ye Y, Zeng Y, Li X, Zhang S, Fang Q, Luo L, et al. HIV infection: an independent risk factor of peripheral arterial disease. J Acquir Immune Defic Syndr. 2010;53(2):276–8.PubMedCrossRef
39.
Bali V, Yermilov I, Coutts K, Legorreta AP. Novel screening metric for the identification of at-risk peripheral artery disease patients using administrative claims data. Vasc Med. 2016;21(1):33–40.PubMedCrossRef
40.
• Gutierrez J, Albuquerque ALA, Falzon L. HIV infection as vascular risk: a systematic review of the literature and meta-analysis. PLoS One. 2017;12(5):e0176686. Provides recent global estimates of rates/risk for multiple CVD etiologies from larger longitudinal studies. PubMedPubMedCentralCrossRef
41.
Yen YF, Chen M, Jen I, Lan YC, Chuang PH, Liu YL, et al. Association of HIV and opportunistic infections with incident stroke: a nationwide population-based cohort study in Taiwan. J Acquir Immune Defic Syndr. 2017;74(2):117–25.PubMedPubMedCentralCrossRef
42.
Sico JJ, Chang CC, So-Armah K, Justice AC, Hylek E, Skanderson M, et al. HIV status and the risk of ischemic stroke among men. Neurology. 2015;84(19):1933–40.PubMedPubMedCentralCrossRef
43.
• Marcus JL, Leyden WA, Chao CR, Chow FC, Horberg MA, Hurley LB, et al. HIV infection and incidence of ischemic stroke. AIDS. 2014;28(13):1911–9. Provides important data on secular trends in stroke incidence rates showing differences differ by HIV status and age group. PubMedCrossRef
44.
Okeke NL, Hicks CB, McKellar MS, Fowler VG Jr, Federspiel JJ. History of AIDS in HIV-infected patients is associated with higher in-hospital mortality following admission for acute myocardial infarction and stroke. J Infect Dis. 2016;213(12):1955–61.PubMedPubMedCentralCrossRef
45.
Chow FC, Bacchetti P, Kim AS, Price RW, Hsue PY. Effect of CD4+ cell count and viral suppression on risk of ischemic stroke in HIV infection. AIDS. 2014;28(17):2573–7.PubMedCrossRef
46.
Chow FC, Price RW, Hsue PY, Kim AS. Greater risk of stroke of undetermined etiology in a contemporary HIV-infected cohort compared with uninfected individuals. J Stroke Cerebrovasc Dis: Off J Natl Stroke Assoc. 2017;26(5):1154–60.CrossRef
47.
Benjamin LA, Allain TJ, Mzinganjira H, Connor MD, Smith C, Lucas S, et al. The role of human immunodeficiency virus-associated vasculopathy in the etiology of stroke. J Infect Dis. 2017;216(5):545–53.PubMedPubMedCentralCrossRef
48.
• Bertrand L, Dygert L, Toborek M. Antiretroviral treatment with Efavirenz disrupts the blood-brain barrier integrity and increases stroke severity. Sci Rep. 2016;6:39738. Pre-clinical study that can and should complement existing exiting work on effects of HIV infection on gastrointestinal barrier function. PubMedPubMedCentralCrossRef
49.
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71.PubMedCrossRef
50.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.PubMedCrossRef
51.
• Klein DB, Leyden WA, Xu L, Chao CR, Horberg MA, Towner WJ, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015;60(8):1278–80. Provides important data on secular trends in myocardial infarction incidence rates showing differences differ by HIV status. PubMedCrossRef
52.
• Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015;60(4):627–38. Provides data to test a frequently repeated theory that HIV accelerates aging and thus diseases common with aging like myocardial infarction. PubMedCrossRef
53.
• Crane HM, Paramsothy P, Drozd DR, Nance RM, Delaney JA, Heckbert SR, et al. Types of myocardial infarction among human immunodeficiency virus-infected individuals in the United States. JAMA Cardiol. 2017;2(3):260–7. Provides increased specificity for describing the association between HIV status and myocardial infarction by differentiating types of myocardial infaraction. PubMedPubMedCentralCrossRef
54.
Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, et al. Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population. J Acquir Immune Defic Syndr. 2017;75(5):568–76.PubMedCrossRefPubMedCentral
55.
Rasmussen LD, Helleberg M, May MT, Afzal S, Kronborg G, Larsen CS, et al. Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. Clin Infect Dis. 2015;60(9):1415–23.PubMed
56.
Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–22.PubMedPubMedCentralCrossRef
57.
• Paisible AL, Chang CC, So-Armah KA, Butt AA, Leaf DA, Budoff M, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr. 2015;68(2):209–16. Provides data enabling comparison of contribution of HIV status versus traditional cardiovascular disease risk factors to absolute cardiovascular disease risk while also demonstrating that even with control of cardiovascular disease risk factors, relative risk of myocardial infarction remains elevated in PLWHA compared to uninfected people. PubMedCrossRef
58.
Echeverria P, Domingo P, Llibre JM, Gutierrez M, Mateo G, Puig J, et al. Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients. Biomed Res Int. 2014;2014:823058.PubMedPubMedCentralCrossRef
59.
Hatleberg CI, Ryom L, El-Sadr W, Smith C, Weber R, Reiss P, et al. Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. AIDS. 2016;30(10):1583–96.PubMedCrossRef
60.
D’Ascenzo F, Cerrato E, Appleton D, Moretti C, Calcagno A, Abouzaki N, et al. Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. Thromb Res. 2014;134(3):558–64.PubMedCrossRef
61.
Carballo D, Delhumeau C, Carballo S, Bahler C, Radovanovic D, Hirschel B, et al. Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. AIDS Res Ther. 2015;12:4.PubMedPubMedCentralCrossRef
62.
Ladapo JA, Richards AK, DeWitt CM, Harawa NT, Shoptaw S, Cunningham WE, et al. Disparities in the quality of cardiovascular care between HIV-infected versus HIV-uninfected adults in the United States: a cross-sectional study. J Am Heart Assoc. 2017;6(11):e007107.PubMedPubMedCentralCrossRef
63.
O’Dwyer EJ, Bhamra-Ariza P, Rao S, Emmanuel S, Carr A, Holloway CJ. Lower coronary plaque burden in patients with HIV presenting with acute coronary syndrome. Open Heart. 2016;3(2):e000511.PubMedPubMedCentralCrossRef
64.
• Feinstein MJ, Mitter SS, Yadlapati A, Achenbach CJ, Palella FJ Jr, Gonzalez PE, et al. HIV-related myocardial vulnerability to infarction and coronary artery disease. J Am Coll Cardiol. 2016;68(18):2026–7. Though a small pilot study, provides interesting mechanistic insight into why prognosis after a myocardial infarction may be worse among PLWHA compared to uninfected people. PubMedPubMedCentralCrossRef
65.
Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59(21):1891–6.PubMedPubMedCentralCrossRef
66.
• Temu TM, Kirui N, Wanjalla C, Ndungu AM, Kamano JH, Inui TS, et al. Cardiovascular health knowledge and preventive practices in people living with HIV in Kenya. BMC Infect Dis. 2015;15:421. Provides data indicating cardiovascular disease risk knowledge and prioritization among PLWHA is low in Kenya, an example of a setting with high HIV prevalence, high cardiovascular disease risk factor prevalence, and constrained resources to tackle a double burden of HIV and CVD simultaneously. PubMedPubMedCentralCrossRef
67.
Rodriguez-Arboli E, Mwamelo K, Kalinjuma AV, Furrer H, Hatz C, Tanner M, et al. Incidence and risk factors for hypertension among HIV patients in rural Tanzania—a prospective cohort study. PLoS One. 2017;12(3):e0172089.PubMedPubMedCentralCrossRef
68.
Naidu S, Ponnampalvanar S, Kamaruzzaman SB, Kamarulzaman A. Prevalence of metabolic syndrome among people living with HIV in developing countries: a systematic review. AIDS Patient Care STDs. 2017;31(1):1–13.PubMedCrossRef
69.
Divala OH, Amberbir A, Ismail Z, Beyene T, Garone D, Pfaff C, et al. The burden of hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in HIV care: consequences for integrated services. BMC Public Health. 2016;16(1):1243.PubMedPubMedCentralCrossRef
70.
Angkurawaranon C, Nitsch D, Larke N, Rehman AM, Smeeth L, Addo J. Ecological study of HIV infection and hypertension in sub-Saharan Africa: is there a double burden of disease? PLoS One. 2016;11(11):e0166375.PubMedPubMedCentralCrossRef
71.
Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T, et al. Population-based assessment of hypertension epidemiology and risk factors among HIV-positive and general populations in rural Uganda. PLoS One. 2016;11(5):e0156309.PubMedPubMedCentralCrossRef
72.
Kingery JR, Alfred Y, Smart LR, Nash E, Todd J, Naguib MR, et al. Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania. Heart. 2016;102(15):1200–5.PubMedCrossRef
73.
Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL. Prevalence of hypertension in HIV/AIDS patients on highly active antiretroviral therapy (HAART) compared with HAART-naive patients at the Limbe regional hospital, Cameroon. PLoS One. 2016;11(2):e0148100.PubMedPubMedCentralCrossRef
74.
Naanyu V, Vedanthan R, Kamano JH, Rotich JK, Lagat KK, Kiptoo P, et al. Barriers influencing linkage to hypertension care in Kenya: qualitative analysis from the LARK hypertension study. J Gen Intern Med. 2016;31(3):304–14.PubMedPubMedCentralCrossRef
75.
Mashinya F, Alberts M, Van Geertruyden JP, Colebunders R. Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: a cross sectional study. AIDS Res Ther. 2015;12:42.PubMedPubMedCentralCrossRef
76.
Muyanja D, Muzoora C, Muyingo A, Muyindike W, Siedner MJ. High prevalence of metabolic syndrome and cardiovascular disease risk among people with HIV on stable ART in southwestern Uganda. AIDS Patient Care STDs. 2016;30(1):4–10.PubMedPubMedCentralCrossRef
77.
Eholie SP, Lacombe K, Krain A, Diallo Z, Ouiminga M, Campa P, et al. Metabolic disorders and cardiovascular risk in treatment-naive HIV-infected patients of sub-saharan origin starting antiretrovirals: impact of westernized lifestyle. AIDS Res Hum Retrovir. 2015;31(4):384–92.PubMedCrossRef
78.
Sander LD, Newell K, Ssebbowa P, Serwadda D, Quinn TC, Gray RH, et al. Hypertension, cardiovascular risk factors and antihypertensive medication utilisation among HIV-infected individuals in Rakai, Uganda. Tropical Med Int Health. 2015;20(3):391–6.CrossRef
79.
Osegbe ID, Soriyan OO, Ogbenna AA, Okpara HC, Azinge EC. Risk factors and assessment for cardiovascular disease among HIV-positive patients attending a Nigerian tertiary hospital. Pan Afr Med J. 2016;23:206.PubMedPubMedCentralCrossRef
80.
Menanga AP, Ngomseu CK, Jingi AM, Mfangam BM, Noubiap JJ, Gweth MN, et al. Patterns of cardiovascular disease in a group of HIV-infected adults in Yaounde, Cameroon. Cardiovasc Diagn Ther. 2015;5(6):420–7.PubMedPubMedCentral
81.
Botha S, Fourie CM, van Rooyen JM, Kruger A, Schutte AE. Cardiometabolic changes in treated versus never treated HIV-infected black South Africans: the PURE study. Heart Lung Circ. 2014;23(2):119–26.PubMedCrossRef
82.
Shaffer D, Hughes MD, Sawe F, Bao Y, Moses A, Hogg E, et al. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in sub-Saharan Africa: A5208 (OCTANE). J Acquir Immune Defic Syndr. 2014;66(2):155–63.PubMedPubMedCentral
83.
Feinstein MJ, Kim JH, Bibangambah P, Sentongo R, Martin JN, Tsai AC, et al. Ideal cardiovascular health and carotid atherosclerosis in a mixed cohort of HIV-infected and uninfected Ugandans. AIDS Res Hum Retrovir. 2017;33(1):49–56.PubMedPubMedCentralCrossRef
84.
Siedner MJ, Kim JH, Nakku RS, Hemphill L, Triant VA, Haberer JE, et al. HIV infection and arterial stiffness among older-adults taking antiretroviral therapy in rural Uganda. AIDS. 2016;30(4):667–70.PubMedCrossRef
85.
Ssinabulya I, Kayima J, Longenecker C, Luwedde M, Semitala F, Kambugu A, et al. Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. PLoS One. 2014;9(2):e89537.PubMedPubMedCentralCrossRef
86.
Schoffelen AF, de Groot E, Tempelman HA, Visseren FL, Hoepelman AI, Barth RE. Carotid intima media thickness in mainly female HIV-infected subjects in rural South Africa: association with cardiovascular but not HIV-related factors. Clin Infect Dis. 2015;61(10):1606–14.PubMedCrossRef
87.
•• Vos A, Tempelman H, Deville W, Barth R, Wensing A, Kretzschmar M, et al. HIV and risk of cardiovascular disease in sub-Saharan Africa: rationale and design of the Ndlovu Cohort Study. Eur J Prev Cardiol. 2017;24(10):1043–50. Will provide much needed prospective, longitudinal cardiovascular disease incidence data in regions of the world with some of the highest HIV burden. PubMedCrossRef
88.
•• Strijdom H, De Boever P, Walzl G, Essop MF, Nawrot TS, Webster I, et al. Cardiovascular risk and endothelial function in people living with HIV/AIDS: design of the multi-site, longitudinal EndoAfrica study in the Western Cape Province of South Africa. BMC Infect Dis. 2017;17(1):41. Will provide much needed prospective, longitudinal cardiovascular disease incidence data in regions of the world with some of the highest HIV burden. PubMedPubMedCentralCrossRef
89.
Soliman EZ, Sharma S, Arasteh K, Wohl D, Achhra A, Tambussi G, et al. Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16 Suppl 1:46–54.PubMedCrossRef
90.
91.
Benjamin LA, Corbett EL, Connor MD, Mzinganjira H, Kampondeni S, Choko A, et al. HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults: a case-control study. Neurology. 2016;86(4):324–33.PubMedPubMedCentralCrossRef
92.
• Lagat DK, DeLong AK, Wellenius GA, Carter EJ, Bloomfield GS, Velazquez EJ, et al. Factors associated with isolated right heart failure in women: a pilot study from western Kenya. Glob Heart. 2014;9(2):249–54. Identifies and highlights important cardiovascular disease risk factors that do not typically get factored into conceptual models of HIV-related cardiovascular disease risk. PubMedCrossRef
93.
Arodiwe I, Ikefuna A, Obidike E, Arodiwe E, Anisuba B, Ibeziako N, et al. Left ventricular systolic function in Nigerian children infected with HIV/AIDS: a cross-sectional study. Cardiovasc J Afr. 2016;27(1):25–9.PubMedPubMedCentralCrossRef
94.
Namuyonga J, Lubega S, Musiime V, Lwabi P, Lubega I. Cardiac dysfunction among Ugandan HIV-infected children on antiretroviral therapy. Pediatr Infect Dis J. 2016;35(3):e85–8.PubMedPubMedCentralCrossRef
95.
Bigna JJ, Nansseu JR, Um LN, Noumegni SR, Sime PS, Aminde LN, et al. Prevalence and incidence of pulmonary hypertension among HIV-infected people in Africa: a systematic review and meta-analysis. BMJ Open. 2016;6(8):e011921.PubMedPubMedCentralCrossRef
96.
Kelly SG, Plankey M, Post WS, Li X, Stall R, Jacobson LP, et al. Associations between tobacco, alcohol, and drug use with coronary artery plaque among HIV-infected and uninfected men in the multicenter AIDS cohort study. PLoS One. 2016;11(1):e0147822.PubMedPubMedCentralCrossRef
97.
Green TC, Kershaw T, Lin H, Heimer R, Goulet JL, Kraemer KL, et al. Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US veteran cohort. Drug Alcohol Depend. 2010;110(3):208–20.PubMedPubMedCentralCrossRef
98.
Kelso NE, Sheps DS, Cook RL. The association between alcohol use and cardiovascular disease among people living with HIV: a systematic review. Am J Drug Alcohol Abuse. 2015;41(6):479–88.PubMedPubMedCentral
99.
Kelso-Chichetto NE, Plankey M, Sheps DS, Abraham AG, Chen X, Shoptaw S, et al. The impact of long-term moderate and heavy alcohol consumption on incident atherosclerosis among persons living with HIV. Drug Alcohol Depend. 2017;181:235–41.PubMedCrossRefPubMedCentral
100.
Lorenz DR, Dutta A, Mukerji SS, Holman A, Uno H, Gabuzda D. Marijuana use impacts midlife cardiovascular events in HIV-infected men. Clin Infect Dis. 2017;65(4):626–35.PubMedPubMedCentralCrossRef
101.
Lucas GM, Atta MG, Fine DM, McFall AM, Estrella MM, Zook K, et al. HIV, cocaine use, and hepatitis C virus: a triad of nontraditional risk factors for subclinical cardiovascular disease. Arterioscler Thromb Vasc Biol. 2016;36(10):2100–7.PubMedPubMedCentralCrossRef
102.
Lesko CR, Moore RD, Tong W, Lau B. Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995-2014. AIDS. 2016;30(9):1447–55.PubMedCrossRef
103.
Pinto Neto L, Dias FR, Bressan FF, Santos CRO. Comparison of the ACC/AHA and Framingham algorithms to assess cardiovascular risk in HIV-infected patients. Braz J Infect Dis. 2017;21(6):577–80.PubMedCrossRef
104.
De Socio GV, Pucci G, Baldelli F, Schillaci G. Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study. BMC Infect Dis 2017; 17(1):414.
105.
• Feinstein MJ, Nance RM, Drozd DR, Ning H, Delaney JA, Heckbert SR, et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the centers for AIDS research network of integrated clinical systems. JAMA Cardiol. 2017;2(2):155–62. Results of this study raises the question of whether we should be looking beyond HIV viremia, CD4 cell count, antiretroviral therapy and traditional cardiovascular disease risk factors in tailoring cardiovascular disease risk prediction for PLWHA. PubMedPubMedCentralCrossRef
106.
Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ Jr, Skarbinski J, Chmiel JS, et al. Cardiovascular disease risk prediction in the HIV outpatient study. Clin Infect Dis. 2016;63(11):1508–16.PubMedCrossRef
107.
Raggi P, De Francesco D, Manicardi M, Zona S, Bellasi A, Stentarelli C, et al. Prediction of hard cardiovascular events in HIV patients. J Antimicrob Chemother. 2016;71(12):3515–8.PubMedCrossRef
108.
Salinas JL, Rentsch C, Marconi VC, Tate J, Budoff M, Butt AA, et al. Baseline, time-updated, and cumulative HIV care metrics for predicting acute myocardial infarction and all-cause mortality. Clin Infect Dis. 2016;63(11):1423–30.PubMedPubMedCentralCrossRef
109.
Herrera S, Guelar A, Sorli L, Vila J, Molas E, Grau M, et al. The Framingham function overestimates the risk of ischemic heart disease in HIV-infected patients from Barcelona. HIV Clin Trials. 2016;17(4):131–9.PubMedCrossRef
110.
Krikke M, Hoogeveen RC, Hoepelman AI, Visseren FL, Arends JE. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models. HIV Med. 2016;17(4):289–97.PubMedCrossRef
111.
Chew KW, Bhattacharya D, McGinnis KA, Horwich TB, Tseng CH, Currier JS, et al. Short communication: coronary heart disease risk by Framingham risk score in hepatitis C and HIV/hepatitis C-coinfected persons. AIDS Res Hum Retrovir. 2015;31(7):718–22.PubMedPubMedCentralCrossRef
112.
Markowicz S, Delforge M, Necsoi C, De Wit S. Cardiovascular risk evaluation of HIV-positive patients in a case-control study: comparison of the D:A:D and Framingham equations. J Int AIDS Soc 2014; 17(4 Suppl 3):19515.
113.
• Friis-Moller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23(2):214–23. Provides an update on a cardiovascular disease risk prediction model built using data from PLWHA. PubMedCrossRef
114.
Haissman JM, Knudsen A, Hoel H, Kjaer A, Kristoffersen US, Berge RK, et al. Microbiota-dependent marker TMAO is elevated in silent ischemia but is not associated with first-time myocardial infarction in HIV infection. J Acquir Immune Defic Syndr. 2016;71(2):130–6.PubMedCrossRef
115.
Srinivasa S, Fitch KV, Lo J, Kadar H, Knight R, Wong K, et al. Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. AIDS. 2015;29(4):443–52.PubMedCrossRef
116.
Al-Kindi SG, Kim CH, Morris SR, Freeman ML, Funderburg NT, Rodriguez B, et al. Brief report: elevated red cell distribution width identifies elevated cardiovascular disease risk in patients with HIV infection. J Acquir Immune Defic Syndr. 2017;74(3):298–302.PubMedPubMedCentralCrossRef
117.
Haissman JM, Haugaard AK, Knudsen A, Kristoffersen US, Seljeflot I, Pedersen KK, et al. Marker of endothelial dysfunction asymmetric dimethylarginine is elevated in HIV infection but not associated with subclinical atherosclerosis. J Acquir Immune Defic Syndr. 2016;73(5):507–13.PubMedCrossRef
118.
Zanni MV, Toribio M, Wilks MQ, Lu MT, Burdo TH, Walker J, et al. Application of a novel CD206+ macrophage-specific arterial imaging strategy in HIV-infected individuals. J Infect Dis. 2017;215(8):1264–9.PubMedPubMedCentralCrossRef
119.
Knudsen A, Hag AM, Loft A, von Benzon E, Keller SH, Moller HJ, et al. HIV infection and arterial inflammation assessed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET): a prospective cross-sectional study. J Nucl Cardiol. 2015;22(2):372–80.PubMedCrossRef
120.
• Rasheed S, Hashim R, Yan JS. Possible biomarkers for the early detection of HIV-associated heart diseases: a proteomics and bioinformatics prediction. Comput Struct Biotechnol J. 2015;13:145–52. Provides an example of how proteomics and bioinformatics can be used to provide new insights into how HIV contributes to cardiovascular disease risk. PubMedPubMedCentralCrossRef
121.
Yong YK, Shankar EM, Westhorpe CL, Maisa A, Spelman T, Kamarulzaman A, et al. Genetic polymorphisms in the CD14 gene are associated with monocyte activation and carotid intima-media thickness in HIV-infected patients on antiretroviral therapy. Medicine (Baltimore). 2016;95(31):e4477.CrossRef
122.
Shendre A, Irvin MR, Aouizerat BE, Wiener HW, Vazquez AI, Anastos K, et al. RYR3 gene variants in subclinical atherosclerosis among HIV-infected women in the Women’s Interagency HIV Study (WIHS). Atherosclerosis. 2014;233(2):666–72.PubMedPubMedCentralCrossRef
123.
El-Far M, Tremblay CL. Gut microbial diversity in HIV infection post combined antiretroviral therapy: a key target for prevention of cardiovascular disease. Curr Opin HIV AIDS. 2017;
124.
Dirajlal-Fargo S, Sattar A, Kulkarni M, Funderburg N, McComsey GA. Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection. HIV Clin Trials. 2017;18(4):156–63.PubMedCrossRefPubMedCentral
125.
Vos AG, Idris NS, Barth RE, Klipstein-Grobusch K, Grobbee DE. Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review. PLoS One. 2016;11(1):e0147484.PubMedPubMedCentralCrossRef
126.
Vos AG, Hulzebosch A, Grobbee DE, Barth RE, Klipstein-Grobusch K. Association between immune markers and surrogate markers of cardiovascular disease in HIV positive patients: a systematic review. PLoS One. 2017;12(1):e0169986.PubMedPubMedCentralCrossRef
127.
Secemsky EA, Scherzer R, Nitta E, Wu AH, Lange DC, Deeks SG, et al. Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals. JACC Heart Fail. 2015;3(8):591–9.PubMedPubMedCentralCrossRef
128.
Rasmussen LJ, Knudsen A, Katzenstein TL, Gerstoft J, Obel N, Jorgensen NR, et al. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study. HIV Med. 2016;17(5):350–7.PubMedCrossRef
129.
Bellasi A, Raggi P, Rossi R, Rochira V, Stentarelli C, Zona S, et al. Intact parathyroid hormone levels are associated with increased carotid intima media thickness in HIV infected patients. Atherosclerosis. 2014;237(2):618–22.PubMedCrossRef
130.
Knudsen A, Katzenstein TL, Benfield T, Jorgensen NR, Kronborg G, Gerstoft J, et al. Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. AIDS. 2014;28(8):1171–9.PubMedCrossRef
131.
Smith JM, Flexner C. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. AIDS. 2017;31(Suppl 2):S173–84.PubMedCrossRef
132.
So-Armah K, Freiberg MS. Cardiovascular disease risk in an aging HIV population: not just a question of biology. Curr Opin HIV AIDS. 2014;9(4):346–54.PubMedPubMedCentralCrossRef
Metadata
Title
HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers
Authors
Kaku So-Armah
Matthew S. Freiberg
Publication date
01-06-2018
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 3/2018
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-018-0400-5

Other articles of this Issue 3/2018

Current HIV/AIDS Reports 3/2018 Go to the issue

The Global Epidemic (SH Vermund, Section Editor)

Network Research Experiences in New York and Eastern Europe: Lessons for the Southern US in Understanding HIV Transmission Dynamics

Complications of Antiretroviral Therapy (GA McComsey, Section Editor)

Continued Interest and Controversy: Vitamin D in HIV

The Global Epidemic (SH Vermund, Section Editor)

Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C

Complications of Antiretroviral Therapy (GA McComsey, Section Editor)

Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update

The Global Epidemic (SH Vermund, Section Editor)

The Policy-Driven HIV Epidemic Among Opioid Users in the Russian Federation

The Global Epidemic (SH Vermund, Section Editor)

Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits